KURA ONCOLOGY, INC. Accounts Receivable
KURA ONCOLOGY, INC. (KURA) had Accounts Receivable of $9.45 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-12
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $9.45M.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $9.35M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $8.80M.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $35.94M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $9.45M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $9.35M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $8.80M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $35.94M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $4.57M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $48.75M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $2.06M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |